Please assess the completion status of the following clinical trial:

Trial Title: Weight Adjusted Low Molecular Weight Heparin in Recurrent Implantation Failure: a Randomized Open Labeled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women ≥18 years and ≤40 years, candidated to a fresh IVF/ICSI cycle with routine ovulation induction protocol~Exclusion Criteria:~v-vCouples candidated to a frozen IVF/ICSI cycle with routine ovulation induction protocol~* Testicular or frozen sperm (TESE procedure not allowed)~* Presence of hormonal disorders not compensated with specific therapy or history of immunological disease (autoimmune thyroiditis, connectivitis, RA, SLE, etc )~* Presence of antiphospholipides autoantibodies or other severe thrombophilia (AT, PS, PC deficiency or homozygous FV Leiden or FIIG20210A, or double eterozygous FV Leiden and FIIG20210A)~* Presence of abnormal platelets count and congenital or acquired coagulopathy ASA or steroid therapy administration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- parnaparin sodium (Type: EXPERIMENTAL): Women in LMWH arm are administered with routine ovulation induction protocol and prophylactic dose of parnaparin sodium (LMWH), starting the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until the delivery or the end of pregnancy. Women in the LMWH arm will be tested for blood cell count twice in the first 10 days of therapy.~Parnaparin will be administered at the dose of 100 IU/kg/day from the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until delivery or the end of the pregnancy.~Used dosages Parnaparin 0.4 4250 UI Parnaparin 0.6 6400 UI
- no treatment (Type: NO_INTERVENTION): Women in the control arm are administered with routine ovulation induction protocol, without the addition of parnaparin sodium.

Based on this trial design, predict the completion outcome and termination type (if applicable).